Immunome IMNM Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $653.48M+356% | $143.35M+45.3% | $98.68M+386% | $20.32M-58.7% | ||
| $660.78M+199% | $221.34M+53.0% | $144.7M+539% | $22.65M-60.0% | ||
| $14.64M+44.7% | $10.11M+388% | $2.07M+204% | $681K-20.4% | ||
| $683.19M+184% | $240.24M+61.7% | $148.54M+518% | $24.05M-58.5% | ||
| $23.27M-27.1% | $31.93M+144% | $13.11M-10.8% | $14.69M+32.3% | ||
| $0-100% | $6.94M-33.9% | $10.49M— | —— | ||
| $44.99M-17.2% | $54.31M+149% | $21.83M+198% | $7.33M-24.6% | ||
| $48.85M-17.3% | $59.08M+106% | $28.66M+288% | $7.39M-24.1% | ||
| $11K+83.3% | $6K+50.0% | $4K+300% | $1K0.0% | ||
| -$728.16M-41.2% | -$515.77M-131% | -$222.81M-92.1% | -$116M-46.6% | ||
| $634.34M+250% | $181.17M+51.1% | $119.88M+620% | $16.65M-65.4% | ||
| $683.19M+184% | $240.24M+61.7% | $148.54M+518% | $24.05M-58.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Immunome cover its short-term obligations?
- Its current ratio is 21.68 — current assets exceed current liabilities.
- Where does Immunome's balance sheet data come from?
- Every line is extracted from Immunome's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.